


## Supplemental figures and table




**sFig. 1. Cell cycle analysis of CT-treated Hepa-6 cells.** Synchronized Hepa1-6 cells incubated with CT for 48 h in a CO<sub>2</sub> incubator were stained with PI and subjected to cell cycle analysis by flow cytometry.




sFig. 2. Determination of cell death of CT-treated Hepa1-6 cells. Hepa1-6 cells seeded in a 12-well plate at  $3 \times 10^5$ /ml/well were incubated with indicated concentrations of CT for 48 h in a CO<sub>2</sub> incubator and before they were harvested, and stained with Annexin V and PI, and analyzed by flow cytometry.




sFig. 3. Flow cytometry determination of leukocyte subsets in the tumors of treated Hepa1-6bearing mice. Tumors removed from Hepa1-6-bearing C57BL/6 mice 24 h after the 3<sup>rd</sup> treatment with CT (100 µg/mouse) and anti-PD-L1 ( $\alpha$ PD-L1, 10 µg/mouse) alone or in combination were enzymatically dissociated into single cell suspension. The single cell suspensions (1x10<sup>6</sup>/sample) were immunostained with labeled antibodies against mouse CD45, CD4, CD8, CD11b, CD11c, and B220. CD4 T cells, CD8 cells, B cells (B220<sup>+</sup>/CD11c<sup>-</sup>), cDCs (CD11c<sup>+</sup>/B220<sup>-</sup>), pDCs (CD11c<sup>+</sup>/B220<sup>+</sup>) and macrophage (M $\phi$ , CD11b<sup>+</sup>/CD11c<sup>-</sup>) were analyzed by gating on CD45<sup>+</sup> populations. Shown are plots of one mouse from each treatment group.





sFig. 4. Flow cytometry analysis of effector/memory (CD62L<sup>-</sup>/CD44<sup>high</sup>) CD8 T cells in the tumors of treated Hepa1-6 Hepa1-6-bearing mice. removed from Hepa1-6-bearing C57BL/6 mice 24 h after the 3<sup>rd</sup> treatment with CT (100 µg/mouse) and anti-PD-L1 ( $\alpha$ PD-L1, 10 µg/mouse) alone or in combination were enzymatically dissociated into single cell suspension. The single cell suspensions (1x10<sup>6</sup>/sample) were immunostained with labeled antibodies against mouse CD45, CD8, CD44, and CD62L. Shown are the gating (**a**) and plots of one mouse from each treatment group (**b**).



sFig. 5. Flow cytometry measurement of effector/memory (CD62L<sup>-</sup>/CD44<sup>high</sup>) CD4 and CD8 T cells in the tumor draining lymph nodes of treated Hepa1-6-bearing mice. Draining lymph nodes (dLN) were removed from Hepa1-6-bearing C57BL/6 mice 24 h after the 3<sup>rd</sup> treatment with CT (100  $\mu$ g/mouse) and anti-PD-L1 ( $\alpha$ PD-L1, 10  $\mu$ g/mouse) alone or in combination and immunostained with labeled antibodies against mouse CD4, CD8, CD44, and CD62L. Shown are the gating (a) and plots of one mouse from each treatment group (b).







sFig. 7. Cytokines expressed in Hepa1-6 tumors in response to treatment. RNAs were extracted from Hepa1-6 tumors resected 24 h after the 3<sup>rd</sup> treatment with CT (100 µg/mouse) and anti-PD-L1 ( $\alpha$ PD-L1, 10 µg/mouse) alone or in combination. The expression of target genes was measured by qPCR, analyzed using Qiagen website, and presented as fold change. \*p<0.001 (n = 7~10).

Primer Name	Company	Primer Number
Mouse CXCL9	Qiagen	PPM029723-200
Mouse CXCL10	Qiagen	PPM02978E-200
Mouse CXCL11	Qiagen	PPM03192C-200
Mouse CCL1	Qiagen	PPM03138C-200
Mouse IFN $\alpha$ 11	Qiagen	PPM03050B-200
Mouse IFN $\beta$	Qiagen	PPMO3594C-200
Mouse TGFβ1	Qiagen	PPM02991B-200
Mouse Perforin	Qiagen	PPM34456B-200
Mouse Granzyme B	Qiagen	PPM05303F-200
Mouse IFNy	Qiagen	PPM03121A-200
Mouse IL-17a	Qiagen	PPM03023A-200
Mouse iNOS	IDT	199797838
Mouse IL-4	Qiagen	PPM03013F-200
Mouse IL-10	Qiagen	PPM03017C-200
Mouse IL-13	IDT	135048668
Mouse TNF $\alpha$	IDT	155731475
Mouse IL-12p40	IDT	155731469
Mouse GAPDH	IDT	135048676

sTable 1. qPCR primers used in the current study